secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001564590-22-028853
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q2 2022 net loss of $18.5M; pipeline on track with NVL-520 data expected H2 2022
--------------------------------------------------------------------------------

- Net loss of $18.5M ($0.38 per share); cash, equivalents and marketable securities $257.0M expected to fund operations into 2024.
- R&D expenses $13.6M, G&A $5.2M for Q2 2022.
- Preliminary dose-escalation data from Phase 1 ARROS-1 trial (NVL-520 for ROS1+ NSCLC) anticipated in H2 2022.
- Dosing initiated in Phase 1 ALKOVE-1 trial (NVL-655 for ALK+ NSCLC); new preclinical data presented at WCLC 2022.
- On track to select two additional development candidates in H2 2022 for ALK compound resistance mutations and HER2 Exon 20 insertions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000156459022028853/0001564590-22-028853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000156459022028853/nuvl-8k_20220810.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer